Journal of Nanobiotechnology,
Journal Year:
2023,
Volume and Issue:
21(1)
Published: March 29, 2023
Abstract
Background
The
past
few
years
have
witnessed
a
significant
increase
in
research
related
to
plant-derived
extracellular
vesicles
(PDEVs)
biological
and
medical
applications.
Using
biochemical
technologies,
multiple
independent
groups
demonstrated
the
important
roles
of
PDEVs
as
potential
mediators
involved
cell-cell
communication
exchange
bio-information
between
species.
Recently,
several
contents
been
well
identified
PDEVs,
including
nucleic
acids,
proteins,
lipids,
other
active
substances.
These
cargoes
carried
by
could
be
transferred
into
recipient
cells
remarkably
influence
their
behaviors
associated
with
human
diseases,
such
cancers
inflammatory
diseases.
Main
body
abstract
This
review
summarizes
latest
updates
regarding
focuses
on
its
role
nanomedicine
applications,
drug
delivery
strategies
develop
diagnostic
therapeutic
agents
for
clinical
management
especially
like
cancers.
Conclusion
Considering
unique
advantages,
high
stability,
intrinsic
bioactivity
easy
absorption,
further
elaboration
molecular
mechanisms
factors
driving
function
will
provide
new
horizons
treatment
disease.
Clinical Science,
Journal Year:
2022,
Volume and Issue:
136(3), P. 197 - 222
Published: Feb. 1, 2022
Abstract
Tumorigenesis
is
a
highly
complex
process,
involving
many
interrelated
and
cross-acting
signalling
pathways.
One
such
pathway
that
has
garnered
much
attention
in
the
field
of
cancer
research
over
last
decade
Hippo
pathway.
Consisting
two
antagonistic
modules,
plays
an
integral
role
both
tumour
suppressive
oncogenic
processes,
generally
via
regulation
diverse
set
genes
involved
range
biological
functions.
This
review
discusses
history
within
context
explores
some
most
recent
discoveries
as
to
how
this
critical
transducer
cellular
can
influence
progression.
A
special
focus
on
various
efforts
therapeutically
target
key
effectors
preclinical
clinical
settings.
Trends in cancer,
Journal Year:
2020,
Volume and Issue:
6(9), P. 757 - 766
Published: May 4, 2020
Cancer
is
a
deadly
disease
that
encompasses
numerous
cellular
modifications.
Among
them,
alterations
in
glycosylation
are
proven
reliable
hallmark
of
cancer,
with
most
biomarkers
used
the
clinic
detecting
cancer-associated
glycans.
Despite
their
clear
potential
as
therapy
targets,
glycans
have
been
overlooked
drug
discovery
strategies.
The
complexity
associated
process,
and
lack
specific
methodologies
to
study
it,
long
hampered
progress.
However,
recent
advances
new
methodologies,
such
glycoengineering
cells
high-throughput
screening
(HTS),
opened
avenues
discovery.
We
envision
glycan-based
targeting
has
start
era
cancer
therapy.
In
this
article,
we
discuss
promise
for
effective
drugs.
Journal of Medicinal Chemistry,
Journal Year:
2019,
Volume and Issue:
63(3), P. 884 - 904
Published: Oct. 8, 2019
Human
DNA
topoisomerase
II
is
an
important
target
in
anticancer
therapy.
Despite
the
clinical
success
of
drugs
that
II,
development
resistant
cancer
cells
can
limit
their
efficacy.
To
maximize
therapeutic
potential
drugs,
combination
therapies
and
multitarget
have
been
suggested
many
studies,
where
use
advantageous
from
a
pharmacokinetic
point
view.
There
are
various
different
options
for
preparation
dual-target
or
multiple-target
inhibitors,
as
both
structurally
(e.g.,
I,
Hsp90,
kinases)
functionally
histone
deacetylases
proteasome)
connected
to
validated
targets.
In
this
Perspective,
we
discuss
scientific
background
behind
targeting
together
with
number
other
targets
therapy,
review
present
status,
further
field.
Signal Transduction and Targeted Therapy,
Journal Year:
2022,
Volume and Issue:
7(1)
Published: Sept. 17, 2022
Abstract
Protein
tyrosine
kinases
(PTKs)
are
a
class
of
proteins
with
kinase
activity
that
phosphorylate
residues
critical
molecules
in
signaling
pathways.
Their
basal
function
is
essential
for
maintaining
normal
cell
growth
and
differentiation.
However,
aberrant
activation
PTKs
caused
by
various
factors
can
deviate
from
the
expected
trajectory
to
an
abnormal
state,
leading
carcinogenesis.
Inhibiting
PTK
could
inhibit
tumor
growth.
Therefore,
inhibitors
(TKIs),
target-specific
PTKs,
have
been
used
treating
malignant
tumors
play
significant
role
targeted
therapy
cancer.
Currently,
drug
resistance
main
reason
limiting
TKIs
efficacy
The
increasing
studies
indicated
microenvironment,
death
resistance,
metabolism,
epigenetic
modification
metabolism
were
deeply
involved
development
TKI
besides
PTK-related
pathways
gene
mutations.
Accordingly,
it
great
significance
study
underlying
mechanisms
find
solutions
reverse
improving
Herein,
we
reviewed
potential
approaches
overcome
aiming
provide
theoretical
basis
TKIs.
Signal Transduction and Targeted Therapy,
Journal Year:
2023,
Volume and Issue:
8(1)
Published: Jan. 16, 2023
Abstract
Head
and
neck
cancer
(HNC)
is
malignant,
genetically
complex
difficult
to
treat
the
sixth
most
frequent
cancer,
with
tobacco,
alcohol
human
papillomavirus
being
major
risk
factors.
Based
on
epigenetic
data,
HNC
remarkably
heterogeneous,
treatment
remains
challenging.
There
a
lack
of
significant
improvement
in
survival
quality
life
patients
HNC.
Over
half
experience
locoregional
recurrence
or
distal
metastasis
despite
current
multiple
traditional
therapeutic
strategies
immunotherapy.
In
addition,
resistance
chemotherapy,
radiotherapy
some
targeted
therapies
common.
Therefore,
it
urgent
explore
more
effective
tolerable
improve
clinical
outcomes
patients.
Recent
therapy
studies
have
focused
identifying
promising
biomarkers
developing
therapies.
A
well
understanding
pathogenesis
contributes
learning
about
its
inner
association,
which
provides
novel
insight
into
development
small
molecule
inhibitors.
this
review,
we
summarized
vital
signaling
pathways
discussed
potential
targets
against
critical
molecules
HNC,
as
presenting
preclinical
animal
models
ongoing
completed
therapy,
may
contribute
favorable
prognosis
Targeted
combination
other
limitations
were
also
discussed.
Advanced Science,
Journal Year:
2021,
Volume and Issue:
8(16)
Published: June 3, 2021
Although
photodynamic
therapy
(PDT)
has
promising
advantages
in
almost
non-invasion,
low
drug
resistance,
and
dark
toxicity,
it
still
suffers
from
limitations
the
lipophilic
nature
of
most
photosensitizers
(PSs),
short
half-life
PS
plasma,
poor
tissue
penetration,
tumor
specificity.
To
overcome
these
enhance
PDT,
liposomes,
as
excellent
multi-functional
nano-carriers
for
delivery,
have
been
extensively
studied
theranostics,
including
liposomal
PS,
targeted
controllable
release,
image-guided
therapy,
combined
therapy.
This
review
provides
researchers
with
a
useful
reference
liposome-based
delivery.
